Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Champions Oncology (CSBR) FCF Margin (2016 - 2026)

Champions Oncology has reported FCF Margin over the past 17 years, most recently at 9.12% for Q1 2026.

  • For Q1 2026, FCF Margin fell 1120.0% year-over-year to 9.12%; the TTM value through Jan 2026 reached 7.14%, up 959.0%, while the annual FY2025 figure was 12.62%, 2486.0% up from the prior year.
  • FCF Margin for Q1 2026 was 9.12% at Champions Oncology, up from 11.39% in the prior quarter.
  • Over five years, FCF Margin peaked at 55.1% in Q2 2025 and troughed at 37.09% in Q3 2023.
  • A 5-year average of 1.9% and a median of 2.08% in 2025 define the central range for FCF Margin.
  • Biggest five-year swings in FCF Margin: crashed -3019bps in 2023 and later skyrocketed 6806bps in 2025.
  • Year by year, FCF Margin stood at 18.78% in 2022, then crashed by -77bps to 4.41% in 2023, then crashed by -148bps to 2.1% in 2024, then tumbled by -443bps to 11.39% in 2025, then grew by 20bps to 9.12% in 2026.
  • Business Quant data shows FCF Margin for CSBR at 9.12% in Q1 2026, 11.39% in Q4 2025, and 3.96% in Q3 2025.